HC Wainwright Has Lowered Expectations for Invivyd (NASDAQ:IVVD) Stock Price

Invivyd (NASDAQ:IVVD - Free Report) had its price objective decreased by HC Wainwright from $10.00 to $5.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Invivyd's Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.17) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.16 EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $0.27 EPS.

Separately, D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research report on Friday, May 16th.

Invivyd Stock Performance

IVVD stock traded up $0.10 during trading on Wednesday, hitting $0.95. The stock had a trading volume of 3,013,670 shares, compared to its average volume of 4,514,604. The stock has a market cap of $113.93 million, a price-to-earnings ratio of -0.48 and a beta of 0.40. The company's 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.74. Invivyd has a 1-year low of $0.35 and a 1-year high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The company had revenue of $11.30 million during the quarter, compared to analysts' expectations of $34.45 million. As a group, sell-side analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC lifted its position in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after purchasing an additional 87,358 shares in the last quarter. Barclays PLC lifted its holdings in Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after buying an additional 9,207 shares in the last quarter. Nuveen LLC purchased a new position in Invivyd in the 1st quarter valued at about $65,000. Invesco Ltd. grew its stake in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after acquiring an additional 71,485 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Invivyd during the first quarter worth about $66,000. Hedge funds and other institutional investors own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.